Effect of digoxin on respiratory muscle performance in patients with COPD

D. Liberman, J. L. Brami, H. Bark, D. Pilpel, D. Heimer

    Research output: Contribution to journalArticlepeer-review

    5 Scopus citations


    The effect of 2 weeks oral digoxin administration on respiratory muscle performance (RMP) in 14 patients with chronic obstructive lung disease (COPD) was investigated in a randomized double-blind placebo-controlled cross-over study. All patients were ambulatory with severe air flow obstruction. FEV1/FVC was 0.44±(SD)0.11, FEV1 was 0.88 ± (SD)0.35 liter/s RMP was assessed by measuring maximal inspiratory pressure (P1max), maximal expiratory pressure (PEmax), and maximal voluntary ventilation. Although these parameters were significantly reduced in the COPD patients, 2 weeks of digoxin administration (with serum levels in the therapeutic range) did not alter any parameter of RMP or spirometry. We conclude that digoxin has no effect on RMPor spirometry in ambulatory patients with severe COPD.

    Original languageEnglish
    Pages (from-to)29-32
    Number of pages4
    Issue number1
    StatePublished - 1 Jan 1991


    • Chronic obstructive lung disease
    • Digoxin
    • Maximal expiratory pressure
    • Maximal inspiratory pressure

    ASJC Scopus subject areas

    • Pulmonary and Respiratory Medicine


    Dive into the research topics of 'Effect of digoxin on respiratory muscle performance in patients with COPD'. Together they form a unique fingerprint.

    Cite this